

Express Mail Label No.: EV 695511581 US

Date of Deposit: December 7, 2005

Attorney Docket No. 25619-501 (Formerly 01/21885)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Schoenfeld *et al.*  
SERIAL NUMBER: 09/806,400 EXAMINER: R. Schwadron  
FILING DATE: March 30, 2001 ART UNIT: 1644  
FOR: COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF  
ATHEROSCLEROSIS

**Mail Stop RCE**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Shoenfeld et al.  
U.S.S.N.: 09/806,400

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25619-501.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Matth Pavao", written in a cursive style.

Ivor R. Elrifi, Reg. No. 39,529  
Matthew Pavao, Reg. No. 50,572  
Attorney/Agent for Applicants  
c/o MINTZ LEVIN  
Tel.: (617) 542-6000  
Fax: (617) 542-2241  
**Customer No.; 30623**

Dated: December 7, 2005

TRA 2095765v.1




Express Mail No.: EV 695511581 US  
Date of Deposit: December 7, 2005

Page 1 of 2  
Attorney Docket No.: 25619-501 (Formerly 01/21885)

Please type a plus sign (+) in this box

PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>		09/806,400	
				<b>Filing Date</b>		March 30, 2001	
				<b>First Named Inventor</b>		Shoenfeld	
				<b>Group Art Unit</b>		1644	
				<b>Examiner Name</b>		R. Schwadron	
				<b>Attorney Docket Number</b>		25619-501	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Patent Document No.</b>	<b>Issue Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
	A1	4,874,769	10/17/89	Youssefyeh et al.	514	314	
	A2	5,348,945	09/20/94	Berberian et al.	514	21	
<b>U.S. PUBLISHED APPLICATION DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Published Application No.</b>	<b>Published Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Foreign Patent Document Office Number</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Date of Publication</b>	<b>Translation Yes No</b>		
	B1	WO 00/20019	SHOENFELD ET AL.	04/13/00			
	B2	WO 02/053092 A2	CARDIMMUNE LTD.	07/11/02			
	B3	EP 1 126 867 B1	SHOENFELD ET AL.	08/29/01			
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.</b>					
	C1	Babei et al. <i>Cardiovasc. Res.</i> , 48:158-167 (2000)					
	C2	Bocan <i>Curr. Pharm. Des.</i> , 4(1):37-52 (1998)					
	C3	Bonnin et al. <i>Biotherapy</i> , abstract only, 10(3):213-221 (1998)					
	C4	Burleigh et al. <i>Biochem. Pharmacol.</i> , 70:334-342 (2005)					
	C5	Chen et al. <i>Circulation</i> , 106:20-23 (2002)					
	C6	Cockerill et al. <i>Clin. Immunol.</i> , abstract only, 112(2):129-135 (2004)					
	C7	Collins et al. <i>Arterioscler. Thromb Biol.</i> , 21:365-371 (2001)					
	C8	Cyrus et al. <i>Circulation</i> , 107:521-523 (2003)					
	C9	Elhage et al. <i>Am. J. Pathol.</i> , 167(1):267-274 (2005)					
	C10	George et al. <i>Circulation</i> , 102:1822-1827 (2000)					



Express Mail No.: EV 695511581 US  
Date of Deposit: December 7, 2005

Page 2 of 2  
Attorney Docket No.: 25619-501 (Formerly 01/21885)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C11	George et al. <i>Lupus</i> , 8:220-226 (1999)
	C12	George et al. <i>Cardiovasc. Res.</i> , 62:603-609 (2004)
	C13	George et al. <i>Clin. Cardiol.</i> , 23:453-456 (2000)
	C14	Harats et al. <i>Curr. Opin. Lipidol.</i> , 12:543-546 (2001)
	C15	Ishibashi et al. <i>J. Clin. Invest.</i> , 92:883-893 (1993)
	C16	Kroeger et al. <i>Herz</i> , <b>abstract only</b> , 29(1):26-31 (2004)
	C17	Li et al. <i>J. Clin. Invest.</i> , 106(4):523-531 (2000)
	C18	Lichtman et al. <i>Arterioscler. Thromb. Vasc. Biol.</i> , 19:1938-1944 (1999)
	C19	Lymaye et al. <i>N. Z. J. Med.</i> , 29:789-793 (1999)
	C20	Maron et al. <i>FASEB J.</i> , <b>abstract 183.9</b> , 14:A1199 (2000)
	C21	Matsuura et al. <i>Clin. Dev. Immunol.</i> , <b>abstract only</b> , 11(2):103-111 (2004)
	C22	Meir et al. <i>Am. Heart J.</i> , 146(2):199-202 (2003)
	C23	Napoli et al. <i>Proc. Natl. Acad. Sci. USA</i> , 99(19):12467-12470 (2002)
	C24	Pech et al. <i>Ann. Biol. Clin.</i> , <b>English abstract only</b> , 50:213-227 (1992)
	C25	Roselaar et al. <i>Arterioscler. Thromb. Vasc. Biol.</i> , 16:1013 (1996)
	C26	Sevil et al. <i>Vet Res.</i> , <b>abstract only</b> , 27(2):117-123 (1996)
	C27	Shen et al. <i>11<sup>th</sup> International Symposium on Atherosclerosis</i> , Paris, <b>abstract 3.P.137</b> , page 227 (1997)
	C28	Sherer et al. <i>Cardiology</i> , 97:2-5 (2002)
	C29	Sherer et al. <i>Cardiology</i> , 95(1):20-24 (2001)
	C30	Stankusheva et al. <i>Vutr. Boles.</i> , <b>abstract only</b> , 27(4):88-91 (1988)
	C31	Tertov et al. <i>11<sup>th</sup> International Symposium on Atherosclerosis</i> , Paris, <b>abstract 3.P.139</b> , page 227 (1997)
	C32	Vaarala et al. <i>Thrombosis and Haemostasis</i> , 75(3):456-459 (1996)
	C33	Wang et al. <i>Atherosclerosis</i> , 162:23-31 (2002)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.